步長製藥(603858.SH):擬與他方合作投資設立寧波步長商貿
格隆匯10月11日丨步長製藥(603858.SH)公佈,為實現公司的“大健康”發展戰略,公司擬與他方合作投資設立寧波步長商貿公司(暫定名,最終名稱以工商部門核准登記為準,“寧波步長商貿”)。
此外,為了推動公司與各方的利益形成共贏局面,為公司及股東創造最大價值,根據《山東步長製藥股份有限公司股權投資項目跟隨投資管理辦法》的相關規定,趙路(寧波步長生命科技有限公司商超事業部總經理)、王海慶(寧波步長生命科技有限公司商超事業部營銷總監)、蔡雲飛(寧波步長生命科技有限公司商超事業部大區經理)、趙學峯(寧波步長生命科技有限公司商超事業部大區經理)、吳東標(寧波步長生命科技有限公司商超事業部大區經理)擬對此次投資進行跟投。 寧波步長生命科技有限公司為公司控股子公司,公司持有其87%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.